Holen Sie sich die Stockscreener-App
19.80
0.05%
0.01
Handel nachbörslich:
19.78
-0.02
-0.10%
Schlusskurs vom Vortag:
$19.79
Offen:
$19.86
24-Stunden-Volumen:
2.24M
Relative Volume:
1.60
Marktkapitalisierung:
$2.42B
Einnahmen:
$460.48M
Nettoeinkommen (Verlust:
$142.80M
KGV:
16.78
EPS:
1.18
Netto-Cashflow:
$221.79M
1W Leistung:
-2.85%
1M Leistung:
-8.88%
6M Leistung:
-10.41%
1J Leistung:
-0.55%
1-Tages-Spanne:
$19.17
$19.96
1-Wochen-Bereich:
$19.17
$21.19
52-Wochen-Spanne:
$19.00
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Vergleichen Sie CPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
19.80 | 2.51B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
What is the next catalyst for Mirum Pharmaceuticals Inc.Trade Risk Report & Safe Capital Growth Stock Tips - khodrobank.com
Can Catalyst Pharmaceuticals Inc. outperform in the next rallyMarket Rally & Free Safe Entry Trade Signal Reports - khodrobank.com
Catalyst Pharmaceuticals Inc.’s volatility index tracking explainedJuly 2025 News Drivers & Expert-Curated Trade Recommendations - Newser
Catalyst Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Levels & Low Risk Entry Point Guides - Newser
Is Catalyst Pharmaceuticals Inc. reversing from oversold territoryBull Run & Real-Time Chart Breakout Alerts - Newser
News impact scoring models applied to Catalyst Pharmaceuticals Inc.July 2025 PostEarnings & Safe Capital Investment Plans - Newser
Tools to assess Catalyst Pharmaceuticals Inc.’s risk profileTrade Volume Report & Daily Entry Point Alerts - Newser
Detecting support and resistance levels for Catalyst Pharmaceuticals Inc.July 2025 Earnings & Verified High Yield Trade Plans - Newser
Is Catalyst Pharmaceuticals Inc. impacted by rising ratesGDP Growth & Fast Exit Strategy with Risk Control - khodrobank.com
Published on: 2025-09-03 23:26:43 - Newser
Statistical indicators supporting Catalyst Pharmaceuticals Inc.’s strengthPortfolio Growth Summary & High Conviction Buy Zone Picks - Newser
How to monitor Catalyst Pharmaceuticals Inc. with trend dashboardsMarket Performance Recap & Daily Technical Stock Forecast Reports - Newser
Risk adjusted return profile for Catalyst Pharmaceuticals Inc. analyzedJuly 2025 Short Interest & Breakout Confirmation Trade Signals - Newser
Using R and stats models for Catalyst Pharmaceuticals Inc. forecasting2025 Price Targets & Free Real-Time Volume Trigger Notifications - Newser
What is Catalyst Pharmaceuticals Inc. s 5 year growth outlookJuly 2025 Short Interest & Stepwise Swing Trade Plans - beatles.ru
What indicators show strength in Catalyst Pharmaceuticals Inc.July 2025 Drop Watch & Weekly Setup with High ROI Potential - Newser
How to read the order book for Catalyst Pharmaceuticals Inc.Trend Reversal & Safe Entry Momentum Tips - Newser
Should you hold or exit Catalyst Pharmaceuticals Inc. nowSwing Trade & Real-Time Volume Trigger Notifications - Newser
Is it time to cut losses on Catalyst Pharmaceuticals Inc.2025 Market WrapUp & Safe Capital Allocation Plans - Newser
Market reaction to Catalyst Pharmaceuticals Inc.’s recent newsWeekly Profit Report & Daily Chart Pattern Signals - Newser
How is Catalyst Pharmaceuticals Inc. managing supply chain issuesJuly 2025 Setups & Growth Oriented Trade Recommendations - khodrobank.com
Smart tools for monitoring Catalyst Pharmaceuticals Inc.’s price actionProduct Launch & Accurate Technical Buy Alerts - Newser
Is Catalyst Pharmaceuticals Inc. in a bullish channelJuly 2025 Technicals & AI Powered Market Entry Ideas - khodrobank.com
How high can Catalyst Pharmaceuticals Inc. stock goShort Setup & AI Powered Market Trend Analysis - Newser
What momentum shifts mean for Catalyst Pharmaceuticals Inc.July 2025 Fed Impact & Stepwise Trade Signal Guides - Newser
Will Catalyst Pharmaceuticals Inc. price bounce be sustainableEarnings Overview Report & Capital Efficiency Focused Strategies - Newser
Should I set a stop loss on Catalyst Pharmaceuticals Inc.Weekly Risk Report & Real-Time Market Sentiment Reports - khodrobank.com
Is Catalyst Pharmaceuticals Inc. gaining market shareWeekly Trade Review & Reliable Entry Point Alerts - khodrobank.com
Is Catalyst Pharmaceuticals Inc. stock a hidden gem2025 Institutional Moves & AI Driven Stock Movement Reports - khodrobank.com
Is Catalyst Pharmaceuticals Inc. stock entering bullish territoryWatch List & Verified Technical Trade Signals - Newser
What is the next catalyst for Eupraxia Pharmaceuticals Inc.2025 Buyback Activity & Fast Moving Stock Watchlists - خودرو بانک
Sector ETF performance correlation with Catalyst Pharmaceuticals Inc.2025 Top Decliners & Step-by-Step Swing Trade Plans - Newser
Heatmap analysis for Catalyst Pharmaceuticals Inc. and competitorsBreakout Watch & Technical Entry and Exit Tips - Newser
Does Catalyst Pharmaceuticals Inc. have pricing powerJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - khodrobank.com
Catalyst Pharmaceuticals Inc. Sees Spike in Bullish Option FlowJuly 2025 Drop Watch & Technical Confirmation Alerts - beatles.ru
Using data models to predict Catalyst Pharmaceuticals Inc. stock movementWeekly Loss Report & Free Low Drawdown Momentum Trade Ideas - Newser
Should you wait for a breakout in Catalyst Pharmaceuticals Inc.Oil Prices & AI Forecast Swing Trade Picks - Newser
Is Catalyst Pharmaceuticals Inc. building a consolidation baseJuly 2025 Review & Technical Buy Zone Confirmation - Newser
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Catalyst Pharmaceuticals Inc-Aktie (CPRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tierney David S | Director |
Aug 27 '25 |
Option Exercise |
2.24 |
50,000 |
112,000 |
405,620 |
| Tierney David S | Director |
Aug 27 '25 |
Sale |
20.20 |
26,000 |
525,200 |
379,620 |
| Miller Steve | Chief Op. & Scientific Officer |
Aug 26 '25 |
Option Exercise |
2.24 |
115,000 |
257,600 |
1,064,663 |
| Miller Steve | Chief Op. & Scientific Officer |
Aug 27 '25 |
Option Exercise |
2.24 |
110,000 |
246,400 |
1,059,663 |
| Miller Steve | Chief Op. & Scientific Officer |
Aug 26 '25 |
Sale |
20.28 |
115,000 |
2,332,200 |
949,663 |
| Daly Richard J | President and CEO |
Aug 26 '25 |
Option Exercise |
2.24 |
50,000 |
112,000 |
249,764 |
| Daly Richard J | President and CEO |
Aug 26 '25 |
Sale |
20.62 |
22,970 |
473,641 |
226,794 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):